TONIX PHARMACEUTICALS HOLDING CORP. Retained Earnings
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) had Retained Earnings of -$935.46 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-10
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$935.46M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$894.91M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$854.72M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$807.80M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$935.46M 10-Q · filed 2026-08-10 |
| 2026-03-31 | -$894.91M 10-Q · filed 2026-05-11 |
| 2025-12-31 | -$854.72M 10-Q · filed 2026-08-10 |
| 2025-09-30 | -$807.80M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$775.79M 10-Q · filed 2025-08-11 |
| 2025-03-31 | -$747.52M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$730.69M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$708.59M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$694.37M 10-Q · filed 2024-08-16 |
| 2024-03-31 | -$615.60M 10-Q · filed 2024-05-13 |
| 2023-12-31 | -$600.66M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$573.34M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$545.36M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$516.99M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$470.04M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$438.36M 10-Q · filed 2022-11-07 |
| 2022-06-30 | -$409.38M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$386.24M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$359.82M 10-K · filed 2023-03-13 |
| 2021-09-30 | -$330.27M 10-Q · filed 2021-11-08 |
| 2021-06-30 | -$311.74M 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$288.19M 10-Q · filed 2021-05-10 |
| 2020-12-31 | -$267.53M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$250.51M 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$238.52M 10-Q · filed 2020-08-10 |
| 2020-03-31 | -$224.34M 10-Q · filed 2020-05-12 |
| 2019-12-31 | -$217.07M 10-K · filed 2021-03-15 |
| 2019-09-30 | -$208.36M 10-Q · filed 2019-11-08 |
| 2019-06-30 | -$200.53M 10-Q · filed 2019-08-12 |
| 2019-03-31 | -$194.69M 10-Q · filed 2019-05-13 |
| 2018-12-31 | -$188.45M 10-K · filed 2020-03-24 |
| 2018-09-30 | -$180.86M 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$175.38M 10-Q · filed 2018-08-13 |
| 2018-03-31 | -$169.30M 10-Q · filed 2018-05-11 |
| 2017-12-31 | -$162.36M 10-K · filed 2019-03-18 |
| 2017-09-30 | -$156.87M 10-Q · filed 2017-11-06 |
| 2017-06-30 | -$151.08M 10-Q · filed 2017-08-11 |
| 2017-03-31 | -$146.30M 10-Q · filed 2017-05-12 |
| 2016-12-31 | -$141.24M 10-K · filed 2018-03-09 |
| 2016-09-30 | -$133.76M 10-Q · filed 2016-11-10 |
| 2016-06-30 | -$126.18M 10-Q · filed 2016-08-05 |
| 2016-03-31 | -$116.37M 10-Q · filed 2016-05-06 |
| 2015-12-31 | -$102.40M 10-K · filed 2017-04-13 |
| 2015-09-30 | -$89.04M 10-Q · filed 2015-11-06 |
| 2015-06-30 | -$75.79M 10-Q · filed 2015-08-07 |
| 2015-03-31 | -$64.03M 10-Q · filed 2015-05-08 |
| 2014-12-31 | -$54.34M 10-K · filed 2016-03-03 |
| 2014-09-30 | -$45.35M 10-Q · filed 2014-11-07 |
| 2014-06-30 | -$37.94M 10-Q · filed 2014-08-08 |
| 2013-12-31 | -$26.73M 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |